Skip to main content

CAFCA

Effect of caffeine on cognition in Alzheimer's disease

Sponsor
University Hospital, Lille
Phase
Drug
Caffeine
Countries

Information about the drug that will be tested in the study

Administration

2 capsules per day during 27 weeks

Is the drug already on the market for another medical condition?

No

Will all participants receive the same drug?

Participants will be selected at random to either receive one of the following options:

  • An oral capsule of Caffeine (200mg) twice daily
  • An oral capsule of placebo (inactive substance identical in appearance to the drug being tested) twice daily

Neither the participant nor his/her doctor will know if the person is receiving the investigational drug or the placebo.

Information about participating in the trial

What are the researchers trying to find out?

The purpose of the study is to evaluate the effect of 30-week caffeine treatment on cognition in Alzheimer's disease at beginning to moderate stages.

How long will the treatment last?

30 weeks

What your involvement will entail?
  • During the study, participants will be asked to complete tests that will assess their memory, learning, functioning (i.e. tests like NTB, MMSE, DAD)
  • Complete some laboratory tests.

Further information on the procedures, tests and number of visits can be obtained from the study team.

Who can participate in this study?

Who can participate in the study?

To take part in the study, participants must:

  • Be 50 years old and older
  • Have a diagnosis of probable Alzheimer’s disease according to the National Institute on Aging/Alzheimer's Association core clinical criteria
  • Have a score >16 points in the MMSE test (a test about your memory). This would suggest that the person has an impairment in their memory that is at a mild stage
  • Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration.
  • If the person is taking treatment for Alzheimer’s disease (donepezil, rivastigmine, galantamine, memantime), the dosing regimen must have been stable within the past 2 months and must remain stable for the duration of the study.
Who cannot participate in the study?

People cannot take part in the study if they have or have experienced:

  • Participant who refuse to adopt a low caffeine diet (i.e. eviction of tea and caffeinated coffee)
  • Ongoing neurological disorders, major psychiatric disorder, systematic vascular disease, intracranial mass or medical condition that may interfere with the safety or study assessments or could be the cause of the cognitive impairment
  • Severe heart disease or rhythm disorder
  • Active smoking
  • A pregnancy for female participants.

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

Information for your doctor

EudraCT Number

2019-003302-27

Clinicaltrials.gov identifier

NCT04570085

Study contact information

Thibaud LEBOUVIER 0033 3 20 44 60 21
thibaud.lebouvier@chru-lille.fr

Link to full text

https://www.clinicaltrials.gov/ct2/show/NCT04570085

The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) on March 2022.

This document has been reviewed by the pharmaceutical company running this trial.

This document has been reviewed by a member of the European Working Group of People with Dementia.

 
Acknowledgement

Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.

Image
ctw_acknowledgment_2022-06